American Century Companies Inc. Has $610,000 Stock Position in Pro-Dex, Inc. $PDEX

American Century Companies Inc. lifted its position in shares of Pro-Dex, Inc. (NASDAQ:PDEX) by 3.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,301 shares of the medical instruments supplier’s stock after buying an additional 355 shares during the quarter. American Century Companies Inc. owned about 0.38% of Pro-Dex worth $610,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Ritholtz Wealth Management raised its stake in Pro-Dex by 30.3% in the 1st quarter. Ritholtz Wealth Management now owns 15,944 shares of the medical instruments supplier’s stock worth $791,000 after purchasing an additional 3,711 shares in the last quarter. Navellier & Associates Inc. acquired a new stake in shares of Pro-Dex in the first quarter valued at approximately $1,094,000. Northern Trust Corp raised its position in shares of Pro-Dex by 14.1% in the fourth quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier’s stock valued at $1,672,000 after buying an additional 4,426 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Pro-Dex by 48.5% in the 1st quarter. Bank of New York Mellon Corp now owns 6,415 shares of the medical instruments supplier’s stock valued at $318,000 after acquiring an additional 2,096 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in Pro-Dex in the 4th quarter valued at $260,000. Institutional investors and hedge funds own 15.28% of the company’s stock.

Pro-Dex Stock Down 16.5%

Shares of NASDAQ:PDEX opened at $38.19 on Friday. The company has a fifty day moving average of $46.18 and a 200-day moving average of $46.79. The company has a market capitalization of $124.50 million, a PE ratio of 14.14 and a beta of -0.04. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.45 and a current ratio of 2.73. Pro-Dex, Inc. has a 52-week low of $22.00 and a 52-week high of $70.26.

Pro-Dex (NASDAQ:PDEX) last announced its quarterly earnings results on Thursday, September 4th. The medical instruments supplier reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.47 by ($0.11). The company had revenue of $17.49 million for the quarter, compared to analyst estimates of $17.90 million. Pro-Dex had a return on equity of 27.49% and a net margin of 13.48%. On average, equities analysts predict that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Analyst Ratings Changes

PDEX has been the subject of several analyst reports. Wall Street Zen cut Pro-Dex from a “buy” rating to a “hold” rating in a report on Saturday, August 16th. Ascendiant Capital Markets boosted their price target on Pro-Dex from $54.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, May 27th. One analyst has rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $56.00.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.